Zhijun Yin

February 27, 2026

Demographic and histologic factors influence risk of colon polyp recurrence

Vanderbilt Health study supports shift toward dynamic surveillance that extends monitoring for patients with specific demographic and histologic risk profiles.

By Leigh MacMillan
December 3, 2025

Large-scale integration of genomics, proteomics and clinical records identifies cancer risk proteins and potential therapeutics

A new study identifies previously unreported protein biomarkers and candidate drug targets across six major cancer types and highlights approved drugs with potential cancer preventive effects.

By Leigh MacMillan
October 15, 2025

New NCI-funded project targets polyp recurrence to prevent colon cancer

The researchers anticipate that their findings will inform personalized colorectal polyp surveillance, guide therapeutic prevention strategies, and ultimately reduce the burden of colorectal cancer nationwide.

By Leigh MacMillan
September 23, 2024

New evaluation system to render AI chatbots safe, empathetic

V-CARES will focus on detecting hallucinations, omissions and misaligned values in AI-generated responses on critical health topics.

By Paul Govern
April 21, 2022

When science spills onto social media

Vanderbilt researchers report that social media posts can offer insights into how the public feels about genome editing, with stances varying across platforms and differing from those of academics and policy makers.

By Paul Govern
September 21, 2020

Throwing weight around on the internet

What users mention in online weight loss forum tracks with how much weight they lose.

By Paul Govern
May 14, 2020

Yin receives early investigator MERIT Award from NCI

Zhijun Yin, PhD, assistant professor of Biomedical Informatics at Vanderbilt University Medical Center, has received the National Cancer Institute’s Method to Extend Research in Time Award (or MERIT Award) for Early Stage Investigators.
By Paul Govern
January 31, 2019

Study finds patient messages help predict medication adherence

Around two-thirds of patients treated for breast cancer will have had hormone-sensitive tumors and, after their initial treatment, will be advised to undergo hormone therapy for five to 10 years to prevent recurrence.
By Paul Govern